Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
83 studies found for:    vaccine adverse reactions | Open Studies
Show Display Options
Download search resultsDownload the search results for:
vaccine adverse reactions | Open Studies (83 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Condition: Smallpox Vaccine Adverse Reaction
Intervention: Biological: Vaccination with ACAM2000
2 Recruiting A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults
Condition: Staphylococcus Aureus Infection
Interventions: Biological: Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml);   Biological: Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml);   Biological: High dosage of Staphylococcus aureus vaccine (60µg/0.6ml);   Biological: Placebo
3 Recruiting A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
Conditions: Hepatitis E;   Hepatitis B
Interventions: Biological: HEV vaccine;   Biological: HBV vaccine
4 Recruiting Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks
Condition: Safety, Pentavalent Vaccine
Intervention: Biological: ComBe Five (Liquid)
5 Not yet recruiting Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old
Condition: Enterovirus 71 Vaccine
Intervention: Biological: two doses enterovirus 71 vaccine
6 Recruiting A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults
Condition: Shigella Sonnei Infection
Interventions: Biological: S. sonnei vaccine 25 μg;   Biological: S. sonnei vaccine 100 μg;   Biological: Menveo;   Biological: Boostrix
7 Not yet recruiting Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
Condition: Cervical Cancer
Interventions: Biological: Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha);   Biological: placebo
8 Not yet recruiting Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months
Condition: Hand Foot and Mouth Disease
Interventions: Biological: the first batch vaccine;   Biological: the second batch vaccine;   Biological: the third batch vaccine
9 Recruiting Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine
Condition: Dengue
Interventions: Biological: Dengue 1,2,3,4 (attenuated) vaccine;   Other: Placebo
10 Not yet recruiting Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)
Condition: Diseases Caused by Streptococcus Pneumoniae Serotypes
Interventions: Biological: 7-valent pneumococcal conjugate vaccine;   Biological: 13-valent pneumococcal polysaccharide conjugate vaccine
11 Recruiting A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine
Condition: Hepatitis B, Chronic
Intervention: Biological: CVI-HBV-002
12 Recruiting HBV Vaccine in Renal Failure Patients
Condition: Renal Failure
Interventions: Biological: Intradermal HBVv with imiquimod;   Biological: Intradermal HBVv with aqueous cream;   Biological: Intramuscular HBVv with aqueous cream
13 Recruiting A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
Condition: Influenza, Human
Interventions: Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine;   Biological: Comparator Quadrivalent Inactivated Influenza Vaccine
14 Recruiting VZV Vaccine for Hematopoietic Stem Cell Transplantation
Condition: Varicella Zoster Infection
Interventions: Biological: Zostavax;   Biological: Normal Saline
15 Unknown  Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
Conditions: High Risk HLA-A2+ Melanoma;   Metastatic Disease
Intervention: Biological: Melanoma vaccine modified to express HLA A2/4-1BB ligand
16 Unknown  Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
Condition: Influenza
Intervention: Biological: 2012 trivalent influenza vaccine
17 Unknown  The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination
Condition: Varicella
Interventions: Biological: HBV-3;   Biological: HBV-6;   Biological: varicella-3;   Biological: varicella-6
18 Recruiting Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
Condition: Typhoid Fever
Intervention: Biological: Vivotif
19 Unknown  Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
Conditions: Immunogenicity;   Reactogenicity
Intervention: Biological: Trivivac vaccine
20 Not yet recruiting P3+ Intervention Phase
Condition: Vaccination
Interventions: Behavioral: Control Site;   Behavioral: Intervention Site;   Behavioral: Patient-level Control Group;   Behavioral: Patient-level Intervention Group

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years